Dr. Margaret Jorgensen joined HTANALYSTS in March 2013 and has over 25 years’ experience in assessing the best available evidence to inform health policy in the medical research, pharmaceutical and biotechnology industries.  

At HTANALYSTS, Margaret leads the development of clinical practice guidelines and the design and conduct of evidence reviews to support healthcare decision-making. She has completed more than 70 rigorous systematic reviews in areas of public health importance and has contributed to the development of numerous published clinical guidelines.

Margaret provides strategic advice on review methodology and works closely with government, clinical and academic stakeholders to incorporate clinical insight into evidence synthesis. She has also served as an evaluator for MSAC on behalf of the Department of Health & Ageing.

Before joining HTANALYSTS, Dr Jorgensen worked with organisations including the Bill & Melinda Gates Foundation, the World Bank and the International AIDS Vaccine Initiative. She delivered evidence-based research to inform policy decisions in neglected diseases.

She has also managed late-phase clinical trials across multiple regions and advised industry and non-industry clients on emerging trends, competitive landscapes and market potential for drugs and vaccines in both commercial and neglected disease settings.

Margaret holds a Bachelor of Medical Science (Hons) from the University of Sydney and a PhD in molecular biology from the University of New South Wales. She completed postdoctoral training at the Harvard T.H. Chan School of Public Health. She has published in peer-reviewed journals and undertaken formal training in GRADE methodology, biostatistics, health technology assessment and project management.